# AKI Biomarkers for Early Detection: Student Handout Updated March 2026 — Biomarkers are now formally part of the KDIGO 2026 draft AKI definition and staging system ## Learning Objectives By the end of this handout, you should be able to: - Explain the limitations of traditional AKI markers (creatinine, urine output) - Identify and compare first-generation biomarkers (NGAL, KIM-1, IL-18, cystatin C) - Understand second-generation biomarkers (TIMP-2, IGFBP-7) and their clinical utility - Apply biomarkers appropriately in high-risk clinical scenarios - Recognize that biomarker combinations outperform single markers ------------------------------------------------------------------------ ## Why New Biomarkers Matter: The Creatinine Problem **The Temporal Gap:** Serum creatinine is a **delayed marker** of kidney injury. It may take 24-48 hours after initial AKI onset before creatinine rises above baseline. By that time, the critical therapeutic window for intervention has often closed. **Why Delay Matters:** - Early intervention with hemodynamic optimization, toxin avoidance, or medication adjustments may prevent progression - Loop diuretics, fluid management, and nephrotoxin avoidance are most effective in early AKI - Once established ATN develops, treatment options become largely supportive **Urine Output Limitations:** - Preserved urine output can mask significant kidney injury - Non-oliguric AKI has better outcomes but still requires recognition - Patients on diuretics may maintain urine output despite declining kidney function **Clinical Pearl:** “The kidney injury exists hours before creatinine tells you it does.” ------------------------------------------------------------------------ ## Traditional Markers: When and How to Use Them ### Serum Creatinine **Pros:** - Widely available, inexpensive - Defines AKI stage (KDIGO criteria) **Cons:** - 24-48 hour lag after initial injury - Affected by muscle mass, age, sex, diet - Not specific for kidney injury vs. other causes of azotemia ### Urine Output **Pros:** - Easy to measure, real-time data **Cons:** - Can be maintained despite significant tubular injury - Non-specific (many conditions reduce urine output) - Doesn’t distinguish injury type or mechanism ------------------------------------------------------------------------ ## First-Generation Biomarkers: Detecting Early Injury These biomarkers identify kidney injury **hours to days before creatinine elevation**. ### Neutrophil Gelatinase-Associated Lipocalin (NGAL) **What It Is:** 25-kilodalton protein rapidly upregulated in kidney tubular cells following injury. **When It Rises:** 3-6 hours post-injury in most clinical settings. **Key Performance:** \| Metric \| Value \| \|——–\|——-\| \| Time to detection \| 3-6 hours post-injury \| \| Lead time over creatinine \| 24-48 hours \| \| Measured in \| Plasma and urine \| \| Common assay \| Point-of-care available \| **Clinical Utility:** - Cardiac surgery: Identifies CSAKI within 4 hours post-op - Sepsis: Early AKI detection before hemodynamic deterioration - Pediatric populations: Especially valuable (smaller baseline creatinine changes) - **Cirrhosis-associated AKI (PP 2.5.6):** NGAL helps distinguish true structural kidney injury (ATN) from functional/prerenal AKI (hepatorenal syndrome) in cirrhotic patients, where creatinine is particularly unreliable due to low muscle mass, impaired hepatic creatine synthesis, and volume overload KDIGO 2026 draft Change NGAL is now a **guideline-recommended** biomarker alongside TIMP-2·IGFBP7 (Rec 2.4.1, 2B). A positive NGAL satisfies the B1 biomarker axis in the new three-axis staging system. **Limitations:** - Elevated in sepsis, burns (not kidney-specific) - Performance varies by clinical context - Requires standardized cutoffs for interpretation **Clinical Pearl:** NGAL is most useful in controlled settings (post-op) where timing of potential injury is known. In cirrhosis, it adds value precisely where creatinine fails. ### Kidney Injury Molecule-1 (KIM-1) **What It Is:** Type 1 transmembrane glycoprotein expressed on injured proximal tubular cells. **Why It’s Special:** Not expressed in healthy kidneys; dramatically upregulated only after injury (high specificity). **Key Features:** - **FDA-approved** for preclinical drug development - Excellence in **ischemic ATN** detection - Predicts drug-induced AKI before creatinine rises (especially platinum-based chemotherapy) - Measured via noninvasive urine testing **Clinical Application:** Monitoring patients receiving known nephrotoxic agents (cisplatin, vancomycin) to detect early injury and modify therapy. **Limitation:** Less extensively validated across all AKI contexts compared to NGAL. ### Interleukin-18 (IL-18) **What It Is:** Inflammatory cytokine elevated in ischemic injury. **Timeline:** Rises 6-12 hours post-injury (slightly later than NGAL). **Key Advantage:** **Synergistic with NGAL** — combining both improves diagnostic accuracy. **Clinical Context:** Particularly useful in: - Sepsis-associated AKI - Post-cardiac surgery AKI - Septic shock requiring risk stratification **Limitation:** Elevated in other inflammatory conditions (not specific to kidney injury). ### Cystatin C **What It Is:** Small protein (13 kDa) produced by all nucleated cells; freely filtered by glomerulus. **Why It’s Different:** Unlike creatinine, NOT affected by: - Muscle mass - Age - Sex - Diet **Clinical Advantage:** Better detection in populations where creatinine is unreliable: - Elderly patients with low muscle mass - Cachectic/critically ill patients - Frail populations **Performance:** - Detects AKI **24-48 hours before serum creatinine** - More accurate eGFR equations when combined with creatinine **Limitation:** Rises more gradually than NGAL or KIM-1 (not true “early” detection). ------------------------------------------------------------------------ ## Second-Generation Biomarkers: Cell Cycle Arrest Markers ### TIMP-2 and IGFBP-7 (Now Guideline-Recommended) KDIGO 2026 draft Change TIMP-2·IGFBP7 and NGAL are now **guideline-recommended** biomarkers for AKI risk assessment (Recommendation 2.4.1, Grade 2B). They are no longer just research tools — they are part of the formal AKI definition and staging system. **Revolutionary Concept:** These don’t detect dead cells or inflammation — they detect **cellular stress** and protective mechanisms. **Biology:** Both proteins are induced by G1 cell cycle arrest — a protective response where tubular cells pause division when DNA damage is detected. **Combined Metric:** NephroCheck® test = \[TIMP-2\] × \[IGFBP-7\] **Clinical use and evidence:** NephroCheck was FDA-cleared for the specified ICU risk-assessment population and 12-hour horizon. Test performance varies by population, timing, comparator, and outcome; do not infer universal superiority for structural-injury detection. Prediction accuracy does not itself demonstrate improved outcomes. [FDA decision summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN130031.pdf). **Assay-specific risk interpretation:** For the original FDA-cleared NephroCheck use, an AKIRisk score \>0.3 is a risk signal for moderate/severe AKI within 12 hours in ICU patients age ≥21 with recent acute cardiovascular or respiratory compromise. It is not a diagnosis, a universal Stage-3 probability, or a dialysis trigger. Follow actual units, intended population, and clinical context. [FDA decision summary](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN130031.pdf). ### The Biomarker Axis: B0/B1 in KDIGO 2026 draft Three-Axis Staging KDIGO 2026 draft introduces biomarkers as the **third axis** of AKI staging alongside creatinine (C0–C3) and urine output (U0–U3): | Biomarker Stage | Definition | |----|----| | **B0** | No biomarker evidence of kidney injury/stress | | **B1** | Positive kidney injury/stress biomarker (TIMP-2·IGFBP7, NGAL, or other validated marker) | **Proposed subclinical AKI (C0/U0/B1):** The KDIGO 2026 AKI/AKD public-review draft proposes a biomarker axis for injury/stress despite no qualifying creatinine or urine-output change. This remains draft terminology, not a final replacement for published routine AKI criteria. **Clinical Pearl:** TIMP-2·IGFBP7 and NGAL are the primary biomarkers that satisfy B1 criteria. A positive result moves a patient from “no AKI” to “subclinical AKI” even with normal Cr and UO. **Limitations:** - Bilirubin interference (\>7.2 g/dL causes false elevation) - Proteinuria interference (\>125 mg/dL) - Not validated across all AKI etiologies yet ------------------------------------------------------------------------ ## Clinical Applications by Setting ### Cardiac Surgery (Highest Evidence Base) **Why It Matters:** AKI occurs in 20-50% of cardiac surgery patients and worsens outcomes. **Recommended Biomarker Strategy:** 1. **Baseline:** Measure TIMP-2/IGFBP-7, cystatin C, NGAL 2. **Post-op 2-4 hours:** Repeat TIMP-2/IGFBP-7 3. **If elevated:** Implement protective measures (optimize hemodynamics, avoid nephrotoxins) 4. **High-risk patients:** Consider RRT earlier if biomarkers show severe elevation **Evidence:** Multi-institutional data shows biomarker-guided RRT timing reduces complications and ICU stays. ### Sepsis and Septic Shock **Challenge:** Multiple competing mechanisms (ischemia, inflammation, endothelial dysfunction) require broader biomarker panel. **Recommended Combination:** - NGAL + IL-18 (detect injury + inflammation) - TIMP-2/IGFBP-7 (assess progression risk) - Cystatin C (baseline renal function) **Clinical Decision:** High-risk biomarker profile should prompt: - Aggressive hemodynamic optimization - Avoidance of additional nephrotoxins - More intensive renal function monitoring ### Nephrotoxic Drug Monitoring (Platinum Chemotherapy) **Special Application:** Detecting drug-induced AKI before irreversible damage. **Biomarker of Choice:** **KIM-1** (detects tubular injury 2 days before creatinine rise) **Clinical Protocol:** 1. Baseline KIM-1 before chemotherapy initiation 2. Serial measurement during treatment (every 2-3 days) 3. If KIM-1 rises \>50% from baseline: consider dose adjustment or treatment modification 4. May prevent progression to clinically significant AKI **Evidence:** Studies show early KIM-1 elevation predicts treatment-limiting nephrotoxicity. ------------------------------------------------------------------------ ## Biomarker Panels: Combining Tests for Better Accuracy **Key Concept:** No single biomarker achieves perfect diagnostic accuracy. Combining markers improves performance. ### Example Panel Strategy | Clinical Scenario | Recommended Panel | Rationale | |----|----|----| | Cardiac surgery, high-risk | TIMP-2/IGFBP-7 + Cystatin C + NGAL | Detect stress, structural damage, GFR | | Septic shock ICU | IL-18 + NGAL + TIMP-2/IGFBP-7 | Inflammation + injury + progression | | Drug monitoring | KIM-1 + NGAL | Tubular toxicity detection | | Cardiac surgery + CKD | All above markers | Multiple risk factors require comprehensive assessment | **Interpretation Strategy:** - **All normal:** Low risk of progression; standard monitoring - **1-2 markers elevated:** Intermediate risk; close observation, optimize conditions - **3+ markers elevated:** High risk; consider early RRT, aggressive nephroprotection ------------------------------------------------------------------------ ## Table: Biomarker Comparison | Biomarker | Time to Rise | Specificity | Test Type | Clinical Use | Limitations | |----|----|----|----|----|----| | Creatinine | 24-48 hrs | Low | Serum | Define AKI stage | Delayed, non-specific | | NGAL | 3-6 hrs | Moderate | Serum/Urine | Early AKI detection | Non-kidney specific | | KIM-1 | 2-4 hrs | High | Urine | Drug-induced AKI | Less validated overall | | IL-18 | 6-12 hrs | Moderate | Urine | Sepsis, ischemia | Non-specific | | Cystatin C | 24-48 hrs | Moderate | Serum | eGFR accuracy | Slower rise than others | | TIMP-2/IGFBP-7 | 12-24 hrs | High | Urine (NephroCheck®) | Progression risk | Bilirubin/protein interference | ------------------------------------------------------------------------ ## Regulatory Status and Clinical Implementation **FDA-Qualified Biomarkers (for drug development):** - Cystatin C - KIM-1 - NGAL - TIMP-2 - IGFBP-7 - Osteopontin - Clusterin This FDA qualification enables pharmaceutical companies to use these in drug trials as evidence of nephrotoxicity or nephroprotection—accelerating drug development. **Commercially Available Tests:** - **NephroCheck®:** TIMP-2 × IGFBP-7 (point-of-care available) - NGAL: Multiple lab platforms - KIM-1: Research assays primarily - Cystatin C: Widely available ------------------------------------------------------------------------ ## Current Guidelines and Evidence-Based Recommendations ### KDIGO 2026 draft Guidelines Position: - **KDIGO 2026 AKI/AKD draft:** Proposed biomarker recommendations remain under public review. Distinguish those proposals from assay-specific FDA clearance and from the published creatinine/urine-output definition of AKI. - Biomarkers form the **third axis (B0/B1)** of the new three-axis AKI staging system - **Subclinical AKI (C0/U0/B1)** is now a recognized staging category — biomarkers alone can define AKI - Should complement, not replace, clinical assessment - Not recommended for routine screening of low-risk patients ### Urine Eosinophils: A Critical Teaching Point Practice Point 2.5.2 (KDIGO 2026 draft) Urine eosinophils have **LOW sensitivity for excluding AIN** (acute interstitial nephritis). A negative urine eosinophil test does NOT rule out AIN. Do not rely on urine eosinophils as a standalone diagnostic test for AIN — clinical suspicion, medication history, and kidney biopsy remain the gold standard. ### Evidence Gap: Biomarker-Guided Treatment Trials Research Opportunity Existing diuretic treatment trials in AKI were conducted **without biomarker-guided enrollment**. Patients were selected based on creatinine and urine output criteria alone. This creates a significant research opportunity: future trials using the C/U/B three-axis staging system for enrollment could identify patients who benefit most from intervention — particularly those with subclinical AKI (C0/U0/B1) who were invisible to prior trial designs. ### Best Practice Implementation: 1. **High-risk settings preferred:** Cardiac surgery, ICU, sepsis 2. **Appropriate comparator:** Compare to baseline when possible 3. **Serial measurement:** Single values less useful than trends 4. **Integrate with clinical context:** Don’t use biomarkers in isolation 5. **Understand limitations:** Biomarkers enhance but don’t replace clinical judgment 6. **Check the B axis:** In high-risk patients, consider biomarker testing even when Cr and UO are normal ------------------------------------------------------------------------ ## Practical Clinical Scenarios ### Scenario 1: Post-Cardiac Surgery Day 1 Patient’s creatinine is 1.1 (baseline 0.9), unchanged from pre-op. Does he need intervention? **Without Biomarkers:** Might reassure—creatinine stable. **With Biomarkers:** TIMP-2/IGFBP-7 = 0.8 (high-risk). Indicates developing AKI despite stable creatinine. **Clinical Action:** Implement nephroprotective measures (optimize hemodynamics, avoid NSAIDs, monitor for progression). Risk-stratified RRT timing. ### Scenario 2: Septic Shock, Day 2 Patient receiving sepsis treatment. Creatinine 1.8 (baseline 1.0). NGAL 400 ng/mL (elevated), IL-18 elevated. **Interpretation:** Active kidney injury with inflammatory component despite antimicrobial therapy. **Clinical Action:** Aggressive hemodynamic optimization, avoid additional nephrotoxins, prepare for possible RRT, consider high-dose vasopressor response. ### Scenario 3: Patient on Cisplatin Chemotherapy KIM-1 rises 150% from baseline after dose 1. **Interpretation:** Early tubular toxicity detected. **Clinical Action:** Dose adjustment/timing change for dose 2, enhanced hydration, avoid concurrent nephrotoxins, may prevent progression to dialysis-requiring AKI. ------------------------------------------------------------------------ ## Practice Questions **Question 1:** A 64-year-old undergoes elective cardiac surgery with CABG. Post-op day 1: creatinine 1.0 (baseline 0.9), urine output 1.8 L/24hr, TIMP-2/IGFBP-7 = 0.95. Which statement is most accurate? A) No AKI is developing; standard post-op care sufficient B) Patient is at high risk for AKI progression; implement nephroprotective measures C) Elevated biomarker indicates existing AKI Stage 2; start RRT D) Biomarkers unreliable in post-op period; ignore and follow creatinine **Answer: B) Use the positive risk result to reassess and monitor.** In the appropriate intended population, a TIMP-2·IGFBP7 result \>0.3 supports increased risk of moderate/severe AKI within 12 hours. Reassess perfusion/congestion, exposures, dosing, urine output, and creatinine. It does not prove Stage-3 AKI will occur or justify automatic fluids. ------------------------------------------------------------------------ **Question 2:** Which biomarker combination would be most appropriate for a 58-year-old receiving cisplatin-based chemotherapy? A) NGAL and IL-18 B) TIMP-2/IGFBP-7 and cystatin C C) KIM-1 and NGAL D) Creatinine and BUN **Answer:** C) KIM-1 and NGAL. For drug-induced (chemotherapy) AKI monitoring, KIM-1 is most sensitive to tubular toxicity and detects injury 2 days before creatinine rise. NGAL adds complementary information. This combination allows early detection permitting dose modification or timing changes. ------------------------------------------------------------------------ **Question 3:** A 72-year-old with septic shock (day 3) has creatinine 2.1 (baseline 1.2). NGAL = 350 ng/mL, IL-18 elevated, TIMP-2/IGFBP-7 = 1.8. Which interpretation is most accurate? A) Multiple mechanisms of kidney injury (ischemia + inflammation + progressive tissue damage) warrant comprehensive management B) Only NGAL is reliable; others are nonspecific C) High biomarker levels indicate end-stage renal disease D) Biomarkers confirm ATN; biopsy needed **Answer:** A) Multiple mechanisms of kidney injury (ischemia + inflammation + progressive tissue damage) warrant comprehensive management. The panel shows: NGAL (early ischemic injury), IL-18 (inflammatory component), and TIMP-2/IGFBP-7 (high risk for progression). This indicates sepsis-associated AKI with multiple pathophysiologic mechanisms requiring aggressive hemodynamic optimization, vasopressor optimization, and heightened vigilance for RRT needs. ------------------------------------------------------------------------ ## Key Takeaways 1. **Creatinine has a lag** — biomarkers detect injury earlier 2. **KDIGO 2026 draft made biomarkers official** — TIMP-2·IGFBP7 and NGAL are now guideline-recommended (Rec 2.4.1, 2B), forming the B axis of three-axis staging 3. **Subclinical AKI (C0/U0/B1) is real** — biomarkers alone can define AKI even with normal Cr and UO 4. **TIMP-2·IGFBP7:** An assay-specific AKI risk tool in a defined ICU population; use its validated time horizon and population, not a universal claim of superiority. 5. **KIM-1 excels at drug-induced AKI** detection 6. **NGAL differentiates ATN from HRS** in cirrhosis (PP 2.5.6) 7. **Urine eosinophils have low sensitivity** for excluding AIN — do not rely on a negative result (PP 2.5.2) 8. **Combinations outperform single markers** for diagnostic accuracy 9. **Clinical context matters** — don’t interpret biomarkers in isolation 10. **Evidence gap exists** — diuretic trials lacked biomarker-guided enrollment, creating research opportunity for C/U/B-guided interventions ------------------------------------------------------------------------ ## See Also ### Related Student Handouts - AKI Workup and Diagnostic Approach - ATN Management - Renal Labs and Imaging ### Clinical Content (01-Clinical-Medicine/Nephrology) - AKI Hub - Full Clinical Reference - Essential Renal Laboratory Tests ### Atomic Notes (ZK) - Cell Cycle Arrest Biomarkers in AKI Detection - Cell Cycle Arrest Biomarkers Updated - Functional Biomarkers in Early AKI ### Butler-COM Resources - Butler COM - Nephrology Deep Dive ------------------------------------------------------------------------ ## Related Resources - AKI Workup Overview - Comprehensive Biomarker Reference - Extended Biomarker Science - Furosemide Stress Test as Functional Assessment ------------------------------------------------------------------------ **Document Type:** Student Handout **Level:** PA/Medical Student **Created:** 2026-02-12 \| **Updated:** 2026-03-29 **Source:** AKI biomarker literature, KDIGO 2026 draft Clinical Practice Guideline for AKI and AKD --- [Website version](https://urinenephrology.org/student-resources/aki/aki-biomarkers-student-handout.html) · Markdown synchronized October 3, 2026.